Table 2.

Association between median week 6 vedolizumab trough level (VTL) and clinical and endoscopic outcomes for all patients.^a

	Median W6 VTL, µg/ml	IQR		Median W6 VTL, µg/ml	IQR	p
W14 remitters	32.5	24.4–48	W14 non-remitters	24.9	15.8–38.3	0.02
W14 remitters plus normal CRP	40.5	27.9–54.1	W14 non-remitters and/or without normal CRP	26.4	15.8–38.4	0.004
W22 remitters	32.4	23.4–49	W22 non-remitters	23.9	15.5–37.4	0.01
W22 remitters plus normal CRP	32.2	22.6–51.7	W22 non-remitters and/or without normal CRP	25.4	15.8–37.6	0.06
W54 remitters	29.8	20.2–50.7	W54 non-remitters	27.06	21.9–35.2	0.36
W54 remitters plus normal CRP	32.4	25.4–53.8	W54 non-remitters and/or without normal CRP	26.7	18.8–40.8	0.08
MH at W54	29.8	16.8–47.9	No MH at W54	26.7	15.8–34.8	0.25

CRP: C-reactive protein; IQR: interquartile range; MH: mucosal healing.

^aMH data are referred to patients having both baseline and follow-up endoscopy.